The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

UBAP2L  -  ubiquitin associated protein 2-like

Homo sapiens

Synonyms: KIAA0144, NICE-4, NICE4, Protein NICE-4, Ubiquitin-associated protein 2-like
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on UBAP2L

  • Patients enrolled in the NICE-4 trial received enoxaparin as a 0.75-mg/kg intravenous bolus followed by abciximab as a 0.25-mg/kg bolus and a 0.125-mcg/kg/min 12-hour infusion [1].
  • Patients in NICE 1 were administered enoxaparin 1.0 mg/kg intravenously (without abciximab) and those enrolled in NICE 4 were administered a reduced dose (0.75 mg/kg) of enoxaparin in combination with standard-dose abciximab intravenously during PCI [2].

Analytical, diagnostic and therapeutic context of UBAP2L

  • Since algorithms for integrating these pharmacotherapies have not been determined, patients undergoing elective PCI were enrolled into 2 distinct and separate studies conducted by the National Investigators Collaborating on Enoxaparin (NICE) study groups (NICE 1 and NICE 4 studies) [2].


  1. Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. Argenti, D., Hoppensteadt, D., Heald, D., Jensen, B., Fareed, J. American journal of therapeutics. (2003) [Pubmed]
  2. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. Kereiakes, D.J., Grines, C., Fry, E., Esente, P., Hoppensteadt, D., Midei, M., Barr, L., Matthai, W., Todd, M., Broderick, T., Rubinstein, R., Fareed, J., Santoian, E., Neiderman, A., Brodie, B., Zidar, J., Ferguson, J.J., Cohen, M. The Journal of invasive cardiology. (2001) [Pubmed]
WikiGenes - Universities